SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): FEBRUARY 3, 2003
EPIX MEDICAL, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 000-21863 04-3030815
--------------- ------------- -------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
71 ROGERS STREET
CAMBRIDGE, MASSACHUSETTS 02142
---------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 250-6000
--------------
ITEM 5. OTHER EVENTS.
On February 3, 2003, the Company announced that enrollment has been completed
for two MS-325 Phase III pivotal clinical trials for the detection of vascular
disease in the pedal and renal arteries.
The press release announcing the enrollment for the two MS-325 Phase II clinical
trials is filed as an exhibit to this Form 8-K, and is incorporated by reference
into this Item 5. The foregoing description of such document and the enrollment
results contemplated therein is qualified in its entirety by reference to such
exhibit.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits
99.1 Press Release of the Company dated February 3, 2003
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Company has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
EPIX MEDICAL, INC.
(Registrant)
Date: February 4, 2003
/S/ PEYTON J. MARSHALL
--------------------------------------
Peyton J. Marshall
Senior Vice-President, Finance and
Administration, Chief Financial Officer
EXHIBIT INDEX
EXHIBIT NUMBER DESCRIPTION
-------------- -----------
99.1 Press Release of the Company dated February 3, 2003